O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520
The DOI matches its Crossref record.
Abstract
CNP520 inhibits the β-site APP cleaving enzyme 1 (BACE-1), leading to reduced formation of amyloid-β (Aβ). It is under clinical development as potentially disease-modifying treatment in asymptomatic subjects at risk of developing Alzheimer’s disease because of their ApoE genotype. This randomized, double-blind, placebo-controlled, first-in-human (FiH) study has been conducted to assess the safety/tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple ascending doses of CNP520. Single ascending doses were orally administered to healthy adults (n=38/14 CNP520/placebo) and elderly subjects ≥60 years (n=50/17), respectively. Multiple ascending doses were administered over two (n=45/18) and four weeks (n=10/2) to elderly only. In addition, ten healthy adults received a single dose of CNP520 under fasted and fed conditions in a cross-over fashion. Safety and tolerability were assessed based on adverse event (AE), laboratory, vital sign, ECG and other safety data. Pharmacodynamic effects were determined in elderly subjects primarily by quantification of Aβ 1-40 concentrations in cerebrospinal fluid (CSF). After single dosing, serial CSF sampling over 36h was performed. After multiple dosing, sampling was done by means of single lumbar punctures at baseline and 24h after last dose (2-week exposure) or at 2 and 4 weeks (4-week exposure). CNP520 concentrations were quantified both in plasma and CSF. CNP520 was safe and well tolerated following single and multiple doses. There was a similar incidence of AEs with CNP520 and placebo. Dose-dependent reduction of Aβ 1-40 concentrations in CSF by >90% after multiple dosing was determined. The extent of Aβ lowering was stable over four weeks of once-daily dosing. Pharmacokinetic properties included lack of relevant food effect and a terminal elimination half-life that allows once-daily dosing. The safety/tolerability, PK and PD data obtained in this FiH study support further development of CNP520 in healthy subjects at risk of Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Rajasekhar, K., & Govindaraju, T. (2018) · RSC Advances · doi:10.1039/c8ra03620a · Cited by 150
BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92
Is It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
“Another important feature is that the drug can decrease Aβ concentration irrespective of APOE4 status, which was demonstrated in the brain of APOE4-transgenic mice and the CSF of humans during phase IIa clinical trial [170, 171].”
Background
Metadata
- Authors
- Ufer, M., Rouzade-Dominguez, M.-L., Huledal, G., Pezous, N., Avrameas, A., David, O., Kretz, S., Kucher, K., Neumann, U., Cha, J.-H., Graf, A., & Lopez-Lopez, C.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-07
- Volume
- 12
- Issue
- 7S_Part_4
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2535694483
- Cited by
- 9
- References
- 0
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520. https://app.cochat.ai/papers/10.1016/j.jalz.2016.06.351
- The paper
- Ufer, M., Rouzade-Dominguez, M.-L., Huledal, G., Pezous, N., Avrameas, A., David, O., Kretz, S., Kucher, K., Neumann, U., Cha, J.-H., Graf, A., & Lopez-Lopez, C. (2016). O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.06.351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.